|Study Finds Ways to Improve Detection of Blood Clots in the
Enhancing Diagnostic Tests Could Reduce Deaths from Pulmonary Embolism
A new study of a commonly used imaging test of the chest to detect potentially
deadly blood clots in the lung shows that extending the scan to the legs — where
the clots typically originate — or adding a standard clinical assessment
significantly improves physicians' abilities to accurately diagnose pulmonary
embolism. A sudden and potentially deadly blockage in a lung artery, pulmonary
embolism affects an estimated 600,000 Americans each year, making it the fourth
most commonly occurring cardiovascular problem in the United States. The multicenter
study was funded by the National Heart, Lung, and Blood Institute (NHLBI) of
the National Institutes of Health (NIH).
The Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II is
the largest study ever conducted to assess the role of contrast-enhanced multidetector
computed tomographic (CT) angiography for diagnosing pulmonary embolism. In the
June 1, 2006, issue of the New England Journal of Medicine, PIOPED researchers
from eight clinical centers report that chest CT angiography alone detects suspected
pulmonary embolism in only 83 percent of patients; in contrast, combined results
of the chest CT angiogram and the leg CT scan detect clots in 90 percent of patients.
The researchers recommend that physicians consider additional test results before
ruling out pulmonary embolism in patients whose scan does not detect clots but
whose clinical assessment suggests a high likelihood of pulmonary embolism.
"Imaging technologies are one of the most rapidly evolving areas of medicine,
and they greatly expand our ability to diagnose and treat disease," said Elias
A. Zerhouni, MD, NIH Director and a board-certified radiologist. "In recent years,
chest CT scans have become the most widely used technique for diagnosing pulmonary
embolism. But, until now, we have not had enough scientific evidence to really
understand how accurate they are for detecting this often-fatal condition."
Pulmonary embolism (PE) leads to death in nearly one-third of untreated cases,
but therapies lower the death rate to between 3 percent and 8 percent. In nine
out of 10 cases, PE begins as a clot in the deep veins of the leg, a condition
known as deep vein thrombosis (DVT). The clot breaks free from the vein and travels
to the lung, where it can block an artery. Commonly used treatments for both
PE and DVT include anti-clotting medications and injections of clot-busting agents.
"There are many effective ways to prevent and treat blood-clotting diseases," noted
NHLBI Director Elizabeth G. Nabel, MD. "Pulmonary embolism is underdiagnosed
and therefore often untreated. If detected early, however, blood clots can often
be prevented from causing permanent damage or death."
In PIOPED II, researchers compared the accuracy of three ways to diagnose blood
clots in 824 patients suspected of having pulmonary embolism: chest CT angiogram
alone, chest CT angiogram with venous-phase imaging (leg CT), and chest CT angiogram
with an objective clinical assessment known as the Wells Score. The Wells Score
is a validated tool to determine the likelihood that a patient has PE based on
characteristics such as signs and symptoms, heart rate, and risk factors. A high
score indicates that a patient has a high probability of having PE. To determine
their accuracy, the tests were compared with the participants' composite results
from other validated diagnostic tests for PE.
Overall, the sensitivity (the ability to detect clots) of the combined chest
CT and leg CT was 90 percent, compared to 83 percent sensitivity of the chest
CT angiogram alone. The specificity (the ability to rule out the presence of
clots) of the chest CT alone compared to the chest CT and leg CT combined was
similar (about 95 percent). A high clinical probability combined with positive
chest CT correctly indicated PE in 96 percent of participants. However, in patients
with a high clinical probability, a negative chest CT result did not confidently
rule out a diagnosis of PE, the researchers report.
"This study suggests that chest CT angiogram for detecting dangerous blood clots
in the lung is good, but sometimes it is not enough," noted Paul D. Stein, MD,
director of research education at St. Joseph Mercy Oakland Hospital in Pontiac,
Michigan, professor of medicine at Wayne State University, and lead author of
the paper. "We can more accurately detect or rule out pulmonary embolism by taking
pictures of the leg veins in addition to pictures of the lung arteries."
The results of the chest CT combined with the patient's clinical probability
assessment were comparable to the results from the combined chest CT and leg
"Our study spells out the strengths and weaknesses of chest CTs for diagnosing
pulmonary embolism, and will help guide physicians on when more tests are needed," added
Stein, who also chaired the PIOPED II steering committee.
During a chest CT angiogram, contrast material (dye) to make the blood vessels
in the lungs more visible is injected into a vein in the patient's arm. The patient
lies on a table as a machine with dozens of detectors rotates around to quickly
take X-ray pictures of the blood vessels — in the lungs for the chest CT
or in the pelvis or thighs for the leg CT. No additional dye is needed for the
leg CT, which can be performed immediately after the chest CT. A computer combines
the images to make detailed pictures.
CT scans are noninvasive and well tolerated by most patients. Adverse effects
are rare and are primarily related to the iodine-based dye that is injected;
possible complications include kidney damage in patients with kidney disease
and allergic reaction. The tests involve some exposure to radiation, but the
benefits outweigh the risks.
Risk factors for pulmonary embolism include blood clots in the leg or a history
of such problems, and certain inherited conditions that increase the risk for
blood clotting. Individuals who recently have been treated for cancer, have been
bedridden, or have had surgery or suffered a fracture in the past few weeks are
also more likely to develop PE. Other risk factors for DVT, which can lead to
PE, include sitting for long periods of time, pregnancy and the 6-week period
after pregnancy, and being overweight or obese. Women who take hormone therapy
or birth control pills are also at increased risk for DVT.
Signs of PE include unexplained shortness of breath, pain with deep breathing,
and coughing up blood. Rapid breathing and a fast heart rate can also indicate
possible PE. In some cases, there are only signs of DVT, such as swelling of
the leg or along the vein in the leg, pain or tenderness in one leg, feeling
of increased warmth in the area of the leg that is swollen, and red or discolored
skin on the affected leg. Other patients do not experience any symptoms or signs
of PE or DVT.
To interview an NHLBI specialist, please contact the NHLBI Communications Office
at (301) 496-4236. To interview Dr. Stein, please contact Jennifer Munro at (248)
Part of the National Institutes of Health, the National Heart, Lung, and
Blood Institute (NHLBI) plans, conducts, and supports research related to the
causes, prevention, diagnosis, and treatment of heart, blood vessel, lung,
and blood diseases; and sleep disorders. The Institute also administers national
health education campaigns on women and heart disease, healthy weight for children,
and other topics. NHLBI press releases and other materials are available online
The National Institutes of Health (NIH) — The Nation's Medical Research
Agency — includes 27 Institutes and Centers and is a component of
the U.S. Department of Health and Human Services. It is the primary federal
agency for conducting and supporting basic, clinical and translational medical
research, and it investigates the causes, treatments, and cures for both common
and rare diseases. For more information about NIH and its programs, visit www.nih.gov.